Correction: The molecular subtyping and precision medicine in triple-negative breast cancer--- based on Fudan TNBC classification

Correction: The molecular subtyping and precision medicine in triple-negative breast cancer--- based on Fudan TNBC classification

Saved in:

Bibliographic Details
Main Authors:	Lijuan Weng, Jianliang Zhou, Shenchao Guo, Nong Xu, Ruishuang Ma
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Series:	Cancer Cell International
Online Access:	https://doi.org/10.1186/s12935-025-03799-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
by: Lijuan Weng, et al.
Published: (2024-03-01)

Retrospective Analysis of Transcriptomic Differences between Triple-Negative Breast Cancer (TNBC) and non-TNBC
by: Çağlar Berkel
Published: (2024-05-01)

Characterization of Disseminated Tumor Cells (DTCs) in Patients with Triple-Negative Breast Cancer (TNBC)
by: Anne Eckardt, et al.
Published: (2025-06-01)

Development of a Cell line Classifier for Precision Subtyping of Triple-Negative Breast Cancer
by: Lu Zhilin, et al.
Published: (2025-01-01)

The Role of Genomics and Transcriptomics in Characterizing and Predicting Patient Response to Treatment in Triple Negative Breast Cancer (TNBC)
by: Franklin Eduardo Corea-Dilbert, et al.
Published: (2025-04-01)

Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
by: Iris Y. Sheng, et al.
Published: (2019-01-01)

Novel Thymoquinone Derivative TQFL28 Inhibits Triple-Negative Breast Cancer (TNBC) Invasiveness In Vitro and In Vivo
by: Jiayue He, et al.
Published: (2025-06-01)

426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology
by: Julia Boehling, et al.
Published: (2025-04-01)

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
by: Yael Bar, et al.
Published: (2025-03-01)

Author Correction: Classification of distinct tendinopathy subtypes for precision therapeutics
by: Chenqi Tang, et al.
Published: (2025-01-01)

Interleukin-1β mediates a tumor-supporting environment prompted by IGF1 in triple-negative breast cancer (TNBC)
by: Domenica Scordamaglia, et al.
Published: (2025-06-01)

Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC)
by: Khashayar Yazdanpanah Ardakani, et al.
Published: (2025-07-01)

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01)

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
by: Xiao-Long Qian, et al.
Published: (2017-01-01)

Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers
by: Rima Saad Bouzid, et al.
Published: (2025-03-01)

Bioinformatics analysis for immune hub genes in BLIS subtype of triple-negative breast cancer
by: Hend Adel, et al.
Published: (2025-07-01)

Identification and validation of neutrophils-related subtypes and prognosis model in triple negative breast cancer
by: Shanqi Li, et al.
Published: (2024-03-01)

Author Correction: Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
by: Miseon Lee, et al.
Published: (2025-03-01)

Caveolin-1 in Tumour Cells is Predominately Expressed in the Basal Subtype of Triple-Negative Breast Carcinoma
by: Savelina Popovska, et al.
Published: (2014-11-01)

Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00
by: Andrea Joaquin Garcia, et al.
Published: (2025-08-01)

Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling, Sustaining Proliferation, Quiescence, and Migration in MDA-MB-231, a Triple-Negative Breast Carcinoma (TNBC) Cell Line
by: Isabel Lemos, et al.
Published: (2025-03-01)

Ferroptosis-related gene signature-based subtype identification of triple-negative breast cancer to prioritize treatment strategies
by: Yongzhen Chen, et al.
Published: (2025-05-01)

Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients
by: Masanori Oshi, et al.
Published: (2020-01-01)

The differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer.
by: Ziyao Li, et al.
Published: (2015-01-01)

Targeting monopolar spindle kinase I (Mps1 or TTK) induces radiosensitization in syngeneic models of triple negative breast cancer (TNBC) and potentiates type I interferon (T1IFN) signaling
by: Kassidy M. Jungles, et al.
Published: (2025-08-01)

Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling Pathways.
by: Yuping Liu, et al.
Published: (2015-01-01)

Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children’s Hospital of Fudan University
by: Xiaowen Qian, et al.
Published: (2024-12-01)

Single-cell ligand–receptor profiling reveals an immunotherapy-responsive subtype and prognostic signature in triple-negative breast cancer
by: Chuanzhi Chen, et al.
Published: (2025-06-01)

Triple-Negative Breast Cancer
by: Quyen D. Chu, et al.
Published: (2012-01-01)

Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer
by: Navakanth Raju Ramayanam, et al.
Published: (2025-07-01)

Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review
by: Ashok Kumar Dogra, et al.
Published: (2025-04-01)

PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy
by: Eunju Shin, et al.
Published: (2025-08-01)

Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer
by: Elie Dagher, et al.
Published: (2020-01-01)

Unveiling the Landscape of PD-L1 Expression and Tumor-Infiltrating Lymphocyte Subtypes in Advanced Triple-Negative Breast Cancer in Brazil
by: Dos Santos ALS, et al.
Published: (2025-04-01)

Investigation of survival and prognostic factors in triple negative molecular subtype male breast cancer patients: A population-based study
by: Ahmet Necati Sanli, et al.
Published: (2024-04-01)

Targeting Mitochondrial Quality Control for the Treatment of Triple-Negative Breast Cancer: From Molecular Mechanisms to Precision Therapy
by: Wanjuan Pei, et al.
Published: (2025-07-01)

TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
by: A. D. Zikiryakhodzhaev, et al.
Published: (2017-06-01)

Characterization of Triple Negative Breast Cancer
by: Bernardo Enrique Heredia Martínez, et al.
Published: (2020-09-01)

Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer
by: Marwa Mohanad, et al.
Published: (2025-02-01)

Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-Targetable vulnerabilities
by: Qing-shan Chen, et al.
Published: (2025-05-01)